Bio Impact Capital LLC Cullinan Oncology, Inc. Transaction History
Bio Impact Capital LLC
- $623 Million
- Q2 2024
A detailed history of Bio Impact Capital LLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Bio Impact Capital LLC holds 7,648,268 shares of CGEM stock, worth $128 Million. This represents 21.42% of its overall portfolio holdings.
Number of Shares
7,648,268
Previous 7,648,268
-0.0%
Holding current value
$128 Million
Previous $130 Million
2.35%
% of portfolio
21.42%
Previous 21.33%
Shares
2 transactions
Others Institutions Holding CGEM
# of Institutions
140Shares Held
65.9MCall Options Held
77.2KPut Options Held
15.9K-
Bvf Inc San Francisco, CA5.75MShares$96.4 Million3.07% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$59.5 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$57.2 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.28MShares$55 Million1.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.87MShares$48.1 Million0.0% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $764M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...